At a glance
- Originator Mitsubishi Pharma Corporation
- Class Acetamides; Anti-inflammatories; Antirheumatics; Piperazines
- Mechanism of Action Interleukin 10 stimulants; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in Japan (PO)
- 30 Jul 2001 New profile
- 30 Jul 2001 Preclinical development for Rheumatoid arthritis in Japan (PO)